title: Antiplatelet therapy, cardiac surgery, and the risk of bleeding: the surgeon's perspective.
abstract: Antiplatelet therapy is widely accepted in the contemporary management of patients         with coronary syndromes. Effective platelet inhibition can cause an increased risk of         bleeding, which is more evident when patients are referred to surgical coronary revascularization.         The cardiac surgeon should be familiar with all new antiplatelet drugs.         In this article we compile the latest information about antiplatelet therapy and         its impact on cardiac surgery.
authors.affiliation: Valley Heart and Vascular Institute, Ridgewood, NJ, USA.
authors.forename: Mariano E
authors.initials: ME
authors.lastname: Brizzio
authors.forename: Alex
authors.initials: A
authors.lastname: Zapolanski
mesh_terms: D001792:Blood Platelets / Q000187:drug effects; D001026:Coronary Artery Bypass / Q000009:adverse effects*; D006331:Heart Diseases / Q000097:blood / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects*; D010979:Platelet Function Tests; D019106:Postoperative Hemorrhage / Q000097:blood / Q000209:etiology* / Q000517:prevention & control; D011237:Predictive Value of Tests; D018570:Risk Assessment; D012307:Risk Factors
chemical_list: D010975:Platelet Aggregation Inhibitors